Floatz logo

Perflutren Lipid Microsphere Intravenous Suspension

Cirrhosis

M.D. Anderson Cancer CenterEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB
OMBITASVIR
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

Perflutren Lipid Microsphere Intravenous Suspension is also rated in:

breast cancerDormant
B
Indicative ·
62 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
62 / 100
View asset →
kidney cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →